SEC Form 4 · accession 0001567619-18-004376
Arbutus Biopharma Corp · ABUS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James R Meyers
Director
Period of report
Oct 18, 2018
Accepted (ET)
Oct 22, 2018 · 1:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001447028
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Share Option (Right to Buy)F1 | $4.71 | Oct 18, 2018 | A | 44,000 | A | — | Oct 18, 2028 | Common Shares | 44,000 | 44,000 | D |
Explanation of responses
- F1The options vest as follows: 1/3 on 10/18/2019; 1/3 on 10/18/2020; and 1/3 on 10/18/2021.